Biogen abandons tau antibody for Alzheimer’s after phase 2 missBiogen has four other Alzheimer’s candidates in its clinical pipeline behind recently-approved Aduhelm, but one of them – Share XBiogen abandons tau antibody for Alzheimer’s after phase 2 misshttps://pharmaphorum.com/news/biogen-abandons-tau-antibody-for-alzheimers-after-phase-2-miss/
Consumer group seeks resignation of top FDA staffers over Aduhelm okayWith the first patient set to receive Biogen’s new Alzheimer’s drug Aduhelm in Rhode Island today, US consumer Share XConsumer group seeks resignation of top FDA staffers over Aduhelm okayhttps://pharmaphorum.com/news/consumer-group-seeks-resignation-of-top-fda-staffers-over-aduhelm-okay/
And then there were three: another FDA adcomm member quits over AduhelmThe fallout over the FDA’s decision to approved Biogen’s Alzheimer’s therapy Aduhelm continues to be felt, with a Share XAnd then there were three: another FDA adcomm member quits over Aduhelmhttps://pharmaphorum.com/news/and-then-there-were-three-another-fda-adcomm-member-quits-over-aduhelm/
FDA slammed over Aduhelm OK as Biogen takes heat for $56k price tagThe FDA “has failed in its responsibility to protect patients and families from unproven treatments with known harms” Share XFDA slammed over Aduhelm OK as Biogen takes heat for $56k price taghttps://pharmaphorum.com/news/fda-slammed-over-aduhelm-ok-as-biogen-takes-heat-for-56k-price-tag/
Jubilation for Biogen, Eisai as FDA says ‘yes’ to aducanumabBiogen and Eisai have defied the naysayers and secured an historic FDA approval for their amyloid-targeting antibody aducanumab Share XJubilation for Biogen, Eisai as FDA says ‘yes’ to aducanumabhttps://pharmaphorum.com/news/jubilation-at-biogen-as-fda-says-yes-to-aducanumab/
Exscientia starts trials of AI-designed Alzheimer’s drugExscientia has advanced a drug candidate for Alzheimer’s disease into human testing, the third clinical-stage project for the Share XExscientia starts trials of AI-designed Alzheimer’s drughttps://pharmaphorum.com/news/exscientia-starts-clinical-trials-of-ai-designed-alzheimers-drug/
Can your typing patterns reveal if you have Alzheimer’s?The neuroQWERTY technology can analyse people’s typing for signs of motor conditions like Parkinson’s disease – and now Share XCan your typing patterns reveal if you have Alzheimer’s?https://pharmaphorum.com/views-and-analysis/can-your-typing-patterns-reveal-if-you-have-alzheimers/
AI platform says Olumiant could be repurposed for Alzheimer’sWith so many novel drug candidates for Alzheimer’s disease failing in clinical development, researchers in the US have Share XAI platform says Olumiant could be repurposed for Alzheimer’shttps://pharmaphorum.com/news/ai-platform-says-olumiant-could-be-repurposed-for-alzheimers/
Alzheimer’s Research UK starts AI-based drug hunt with ExscientiaMedical charity Alzheimer’s Research UK has teamed up with artificial intelligence specialist Exscientia to find new drug treatments Share XAlzheimer’s Research UK starts AI-based drug hunt with Exscientiahttps://pharmaphorum.com/news/alzheimers-research-uk-starts-ai-based-drug-hunt-with-exscientia/
